Fipexide: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
| verifiedrevid = 443216648 | | verifiedrevid = 443216648 | ||
| IUPAC_name = 1-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-<br>2-(4-chlorophenoxy)ethanone | | IUPAC_name = 1-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-<br>2-(4-chlorophenoxy)ethanone | ||
| image = Fipexide. | | image = Fipexide.png | ||
<!--Clinical data--> | <!--Clinical data--> | ||
| Line 40: | Line 40: | ||
| StdInChIKey = BFUJHVVEMMWLHC-UHFFFAOYSA-N | | StdInChIKey = BFUJHVVEMMWLHC-UHFFFAOYSA-N | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Fipexide''' ('''Attentil''', '''Vigilor''') is a [[psychoactive drug]] of the [[piperazine]] [[chemical class]] which was developed in [[Italy]] in 1983.<ref>Missale C, Pasinetti G, Govoni S, Spano PF, Trabucchi M. Fipexide: a new drug for the regulation of dopaminergic system at the macromolecular level. Bollettino Chimico Farmaceutico. 1983 Feb;122(2):79-85.</ref> It was used as a [[nootropic]] drug in Italy and [[France]], mainly for the treatment of senile dementia,<ref>Bompani R, Scali G. Fipexide, an effective cognition activator in the elderly: a placebo-controlled, double-blind clinical trial. Current Medical Research and Opinion. 1986;10(2):99-106.</ref> but is no longer in common use due to the occurrence of rare adverse drug reactions including [[fever]]<ref>Guy C, Blay N, Rousset H, Fardeau V, Ollagnier M. Fever caused by fipexide. Evaluation of the national pharmacovigilance survey. Therapie. 1990 Sep-Oct;45(5):429-31.</ref> and [[hepatitis]]. Fipexide is similar in action to other nootropic drugs such as [[piracetam]] and is structurally similar to another more well-known nootropic, [[centrophenoxine]]. Chemically, it is an amide union of [[parachlorophenoxyacetate]] and [[methylenedioxybenzylpiperazine]] (MDBZP), and has been shown to metabolize to the latter, which plays a significant role in its effects. | '''Fipexide''' ('''Attentil''', '''Vigilor''') is a [[psychoactive drug]] of the [[piperazine]] [[chemical class]] which was developed in [[Italy]] in 1983.<ref>Missale C, Pasinetti G, Govoni S, Spano PF, Trabucchi M. Fipexide: a new drug for the regulation of dopaminergic system at the macromolecular level. Bollettino Chimico Farmaceutico. 1983 Feb;122(2):79-85.</ref> It was used as a [[nootropic]] drug in Italy and [[France]], mainly for the treatment of senile dementia,<ref>Bompani R, Scali G. Fipexide, an effective cognition activator in the elderly: a placebo-controlled, double-blind clinical trial. Current Medical Research and Opinion. 1986;10(2):99-106.</ref> but is no longer in common use due to the occurrence of rare adverse drug reactions including [[fever]]<ref>Guy C, Blay N, Rousset H, Fardeau V, Ollagnier M. Fever caused by fipexide. Evaluation of the national pharmacovigilance survey. Therapie. 1990 Sep-Oct;45(5):429-31.</ref> and [[hepatitis]]. Fipexide is similar in action to other nootropic drugs such as [[piracetam]] and is structurally similar to another more well-known nootropic, [[centrophenoxine]]. Chemically, it is an amide union of [[parachlorophenoxyacetate]] and [[methylenedioxybenzylpiperazine]] (MDBZP), and has been shown to metabolize to the latter, which plays a significant role in its effects. | ||
==See also== | ==See also== | ||
* [[Befuraline]] | * [[Befuraline]] | ||
==References== | ==References== | ||
| Line 52: | Line 56: | ||
{{Nootropics}} | {{Nootropics}} | ||
[[Category:Nootropics]] | [[Category:Nootropics]] | ||
[[Category:Piperazines]] | [[Category:Piperazines]] | ||
[[Category:Amides]] | [[Category:Amides]] | ||
[[Category:Phenol ethers]] | [[Category:Phenol ethers]] | ||
[[Category:Organochlorides]] | [[Category:Organochlorides]] | ||
[[Category: | [[Category:Drug]] | ||
Revision as of 15:23, 13 April 2015
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C20H21ClN2O4 |
| Molar mass | 388.845 g/mol |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
|
WikiDoc Resources for Fipexide |
|
Articles |
|---|
|
Most recent articles on Fipexide |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Fipexide at Clinical Trials.gov Clinical Trials on Fipexide at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Fipexide
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating Fipexide Risk calculators and risk factors for Fipexide
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Fipexide |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Fipexide (Attentil, Vigilor) is a psychoactive drug of the piperazine chemical class which was developed in Italy in 1983.[1] It was used as a nootropic drug in Italy and France, mainly for the treatment of senile dementia,[2] but is no longer in common use due to the occurrence of rare adverse drug reactions including fever[3] and hepatitis. Fipexide is similar in action to other nootropic drugs such as piracetam and is structurally similar to another more well-known nootropic, centrophenoxine. Chemically, it is an amide union of parachlorophenoxyacetate and methylenedioxybenzylpiperazine (MDBZP), and has been shown to metabolize to the latter, which plays a significant role in its effects.
See also
References
- ↑ Missale C, Pasinetti G, Govoni S, Spano PF, Trabucchi M. Fipexide: a new drug for the regulation of dopaminergic system at the macromolecular level. Bollettino Chimico Farmaceutico. 1983 Feb;122(2):79-85.
- ↑ Bompani R, Scali G. Fipexide, an effective cognition activator in the elderly: a placebo-controlled, double-blind clinical trial. Current Medical Research and Opinion. 1986;10(2):99-106.
- ↑ Guy C, Blay N, Rousset H, Fardeau V, Ollagnier M. Fever caused by fipexide. Evaluation of the national pharmacovigilance survey. Therapie. 1990 Sep-Oct;45(5):429-31.